INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ 1) pregnancy, breast-feeding women, or female      │ pregnancy, breast-feeding women, or female         │     100 │
│ patients of childbearing potential but did not     │ patients of childbearing potential but did not     │         │
│ take contraceptive measures;2) existing severe     │ take contraceptive measures;2) existing severe     │         │
│ acute infection and is not controlled; or purulent │ acute infection and is not controlled; or purulent │         │
│ and chronic infection, delayed healing wounds; 3)  │ and chronic infection, delayed healing wounds; 3)  │         │
│ the original severe heart disease, including       │ the original severe heart disease, including       │         │
│ congestive heart failure, uncontrolled high-risk   │ congestive heart failure, uncontrolled high-risk   │         │
│ arrhythmias, unstable angina, myocardial           │ arrhythmias, unstable angina, myocardial           │         │
│ infarction, severe heart valve disease and         │ infarction, severe heart valve disease and         │         │
│ resistant hypertension; 4) suffering from          │ resistant hypertension; 4) suffering from          │         │
│ neurological and psychiatric diseases or mental    │ neurological and psychiatric diseases or mental    │         │
│ disorders is not easy to control, poor compliance, │ disorders is not easy to control, poor compliance, │         │
│ and can not be described with treatment            │ and can not be described with treatment            │         │
│ responders; primary brain or central nervous       │ responders; primary brain or central nervous       │         │
│ metastasis disease has not been controlled, with   │ metastasis disease has not been controlled, with   │         │
│ significant cranial hypertension or                │ significant cranial hypertension or                │         │
│ neuropsychiatric symptoms; 5) have bleeding        │ neuropsychiatric symptoms; 5) have bleeding        │         │
│ tendencies; 6) other researchers believe that      │ tendencies; 6) other researchers believe that      │         │
│ patients should not participate in the present     │ patients should not participate in the present     │         │
│ trial                                              │ trial                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ 1) histologically confirmed (patients not          │ histologically confirmed (patients not receiving a │      99 │
│ receiving a single sputum cytology diagnosis) non- │ single sputum cytology diagnosis) non-small cell   │         │
│ small cell lung cancer patients,with wild-type     │ lung cancer patients,with wild-type EGFR and ALK-  │         │
│ EGFR and ALK-negative; 2) According to IASLC2009   │ negative; 2) According to IASLC2009 new TNM        │         │
│ new TNM staging of lung cancer stage ⅢB or Ⅳ,      │ staging of lung cancer stage <U+2162>B or          │         │
│ previously untreated or relapsed after 1 year of   │ <U+2163>, previously untreated or relapsed after 1 │         │
│ lung cancer resection; 3) have at least one        │ year of lung cancer resection; 3) have at least    │         │
│ evaluable lesions,according to version 1.1 of the  │ one evaluable lesions,according to version 1.1 of  │         │
│ standard in accordance with a judgment             │ the standard in accordance with a judgment         │         │
│ RECIST(longest diameter on a spiral CT at least    │ RECIST(longest diameter on a spiral CT at least    │         │
│ 10mm,on a regular CT longest diameter at least     │ 10mm,on a regular CT longest diameter at least     │         │
│ 20mm); 4) Male or female, aged 18 to 75 years; 5)  │ 20mm); 4) Male or female, aged 18 to 75 years; 5)  │         │
│ ECOG PS 0 or 1; 6) expected survival at least 3    │ ECOG PS 0 or 1; 6) expected survival at least 3    │         │
│ months; 7) adequate hematological function:        │ months; 7) adequate hematological function:        │         │
│ absolute neutrophil count (ANC) at least 2×10\^9/L │ absolute neutrophil count (ANC) at least 2×10^9/L  │         │
│ and platelet count at least 100×10\^9/L and        │ and platelet count at least 100×10^9/L and         │         │
│ hemoglobin at least 9 g/dL; 8) adequate liver      │ hemoglobin at least 9 g/dL; 8) adequate liver      │         │
│ function: total bilirubin less than upper limit of │ function: total bilirubin less than upper limit of │         │
│ normal (ULN); AST and ALT less than 2.5 times      │ normal (ULN); AST and ALT less than 2.5 times      │         │
│ upper limit of normal (ULN); alkaline phosphatase  │ upper limit of normal (ULN); alkaline phosphatase  │         │
│ less than 5 times the upper limit of normal (ULN); │ less than 5 times the upper limit of normal (ULN); │         │
│ 9) adequate renal function: serum creatinine less  │ 9) adequate renal function: serum creatinine less  │         │
│ than upper limit of normal (ULN) or calculated     │ than upper limit of normal (ULN) or calculated     │         │
│ creatinine clearance at least 60 mL/min; 10) ECG   │ creatinine clearance at least 60 mL/min; 10) ECG   │         │
│ is normal, there is no non-healing wounds on the   │ is normal, there is no non-healing wounds on the   │         │
│ body; 11) had not received previous treatment      │ body; 11) had not received previous treatment      │         │
│ anticancer drugs, or had only received for         │ anticancer drugs, or had only received for         │         │
│ previous non-metastatic tumors adjuvant or         │ previous non-metastatic tumors adjuvant or         │         │
│ neoadjuvant chemotherapy, but when you start to    │ neoadjuvant chemotherapy, but when you start to    │         │
│ study treatment has ended more than 6 months; 12)  │ study treatment has ended more than 6 months; 12)  │         │
│ have conducted previous surgery patients required  │ have conducted previous surgery patients required  │         │
│ to study treatment was started more than four      │ to study treatment was started more than four      │         │
│ weeks, and the patient had recovered; 13) have an  │ weeks, and the patient had recovered; 13) have an  │         │
│ intact uterus in women prior to enrollment in the  │ intact uterus in women prior to enrollment in the  │         │
│ study must have a negative pregnancy test result   │ study must have a negative pregnancy test result   │         │
│ (unless it is already 24 months of amenorrhea)     │ (unless it is already 24 months of amenorrhea)     │         │
│ within 28 days. If the pregnancy test from the     │ within 28 days. If the pregnancy test from the     │         │
│ first administration more than seven days, urine   │ first administration more than seven days, urine   │         │
│ pregnancy test is required for authentication      │ pregnancy test is required for authentication      │         │
│ (less than 7 days before the first dose); 14)      │ (less than 7 days before the first dose); 14)      │         │
│ previous to biological agents, particularly E.coli │ previous to biological agents, particularly E.coli │         │
│ genetically engineered products without serious    │ genetically engineered products without serious    │         │
│ allergic reactions; 15) signed informed consent    │ allergic reactions; 15) signed informed consent    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ pregnancy, breast-feeding women, or female         │       6 │
│                                   │ patients of childbearing potential but did not     │         │
│                                   │ take contraceptive measures;2) existing severe     │         │
│                                   │ acute infection and is not controlled; or purulent │         │
│                                   │ and chronic infection, delayed healing wounds; 3)  │         │
│                                   │ the original severe heart disease, including       │         │
│                                   │ congestive heart failure, uncontrolled high-risk   │         │
│                                   │ arrhythmias, unstable angina, myocardial           │         │
│                                   │ infarction, severe heart valve disease and         │         │
│                                   │ resistant hypertension; 4) suffering from          │         │
│                                   │ neurological and psychiatric diseases or mental    │         │
│                                   │ disorders is not easy to control, poor compliance, │         │
│                                   │ and can not be described with treatment            │         │
│                                   │ responders; primary brain or central nervous       │         │
│                                   │ metastasis disease has not been controlled, with   │         │
│                                   │ significant cranial hypertension or                │         │
│                                   │ neuropsychiatric symptoms; 5) have bleeding        │         │
│                                   │ tendencies; 6) other researchers believe that      │         │
│                                   │ patients should not participate in the present     │         │
│                                   │ trial                                              │         │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 75 Years │ pregnancy, breast-feeding women, or female         │       6 │
│                                   │ patients of childbearing potential but did not     │         │
│                                   │ take contraceptive measures;2) existing severe     │         │
│                                   │ acute infection and is not controlled; or purulent │         │
│                                   │ and chronic infection, delayed healing wounds; 3)  │         │
│                                   │ the original severe heart disease, including       │         │
│                                   │ congestive heart failure, uncontrolled high-risk   │         │
│                                   │ arrhythmias, unstable angina, myocardial           │         │
│                                   │ infarction, severe heart valve disease and         │         │
│                                   │ resistant hypertension; 4) suffering from          │         │
│                                   │ neurological and psychiatric diseases or mental    │         │
│                                   │ disorders is not easy to control, poor compliance, │         │
│                                   │ and can not be described with treatment            │         │
│                                   │ responders; primary brain or central nervous       │         │
│                                   │ metastasis disease has not been controlled, with   │         │
│                                   │ significant cranial hypertension or                │         │
│                                   │ neuropsychiatric symptoms; 5) have bleeding        │         │
│                                   │ tendencies; 6) other researchers believe that      │         │
│                                   │ patients should not participate in the present     │         │
│                                   │ trial                                              │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 52.75
OverAll Ratio: 75.375
